• Mashup Score: 0

    New research has illustrated the strides being made to apply modern artificial intelligence (AI) computing methods to oncology, according to new findings to be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Researchers have long investigated the potential of AI to transform cancer care and improve patient outcomes. According to Amara’s Law, individuals tend to overestimate the short-term impacts of technology but underestimate its long-term effects. However, caution may be

    Tweet Tweets with this article
    • ➡️Future of AI in cancer care @ASCOPost article linking ESMO GROW (#RWD reporting standards) with #AI applied to #oncology and the new @myESMO RWD and Digital Oncology Journal @OncologyAdvance https://t.co/3b1VrgQxVb https://t.co/oKksEd8wyR

  • Mashup Score: 0

    The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The conference provides opportunities for attendees to hear from world-renowned researchers on the latest treatments, learn about ways to man…

    Tweet Tweets with this article
    • .@CharlesSwanton was also our keynote speaker for @LUNGevity's #ILCSC23 and did a phenomenal job on this topic! Everyone can view his talk by registering for free here: https://t.co/tha2bpruei All sessions will be available through Dec 21, 2023! https://t.co/JWRCz428xs

  • Mashup Score: 0

    In her May 2023 Editor’s Corner, Brea Lipe, MD, discussed the dark side of chime ric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Given their high and durable response rates, there has been much excitement around the use of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), though various challenges have hindered widespread implementation of these therapies. Here, a reader continues the conversation, raising questions about whether patients with MM should

    Tweet Tweets with this article
    • Ide-cel and cilta-cel, two CAR T-cell therapies, have shown high response rates in patients; however, as the treatment landscape for #CAR T-cell therapy continues to change, discussions on navigating barriers to their widespread implementation remain key. https://t.co/GXsPKX0iNo

  • Mashup Score: 1
    Class and the City - 5 month(s) ago

    The FCA’s consultation on diversity and inclusion will be out of step if it fails to tackle this aspect of the barriers to success

    Tweet Tweets with this article
    • Class and the @cityoflondon : UK @TheFCA ’s consultation on diversity and inclusion will be out of step if it fails to tackle this aspect of the barriers to success https://t.co/1i4IYrlwg4 via @NickBent https://t.co/V1zppb8703